Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
APRE 
Aprea Therapeutics Inc (APRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: APRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.5
1 Year Target Price $10.5
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.93% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.64M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 3 | Beta 1.56 | 52 Weeks Range 1.19 - 5.00 | Updated Date 11/6/2025 |
52 Weeks Range 1.19 - 5.00 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2868.3% |
Management Effectiveness
Return on Assets (TTM) -39.12% | Return on Equity (TTM) -67.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7910813 | Price to Sales(TTM) 9.09 |
Enterprise Value -7910813 | Price to Sales(TTM) 9.09 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.35 | Shares Outstanding 5825261 | Shares Floating 4635801 |
Shares Outstanding 5825261 | Shares Floating 4635801 | ||
Percent Insiders 11.3 | Percent Institutions 31.2 |
Upturn AI SWOT
Aprea Therapeutics Inc
Company Overview
History and Background
Aprea Therapeutics, Inc. is a biopharmaceutical company specializing in cancer therapies. Founded to develop and commercialize therapies reactivating mutant p53 tumor suppressor protein.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing novel cancer therapies that reactivate the mutant p53 tumor suppressor protein.
Leadership and Structure
Aprea Therapeutics Inc's leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure involves various departments including research and development, clinical operations, and commercial strategy.
Top Products and Market Share
Key Offerings
- Eprenetapopt: A small molecule drug designed to reactivate mutant p53. Currently in clinical trials for various hematologic malignancies and solid tumors. No significant market share or revenue at this time due to being in clinical development. Competitors include companies developing therapies for cancers with p53 mutations.
Market Dynamics
Industry Overview
The oncology market is highly competitive and rapidly evolving, with continuous advancements in targeted therapies and immunotherapies.
Positioning
Aprea Therapeutics is positioned as a clinical-stage biopharmaceutical company focused on developing novel cancer therapies targeting the p53 pathway. Its competitive advantage lies in its unique approach to reactivating mutant p53.
Total Addressable Market (TAM)
The total addressable market for p53-targeted therapies is substantial, given the high prevalence of p53 mutations in cancer. The TAM is estimated to be in the billions of dollars. Aprea Therapeutics Inc aims to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Novel approach to cancer therapy (p53 reactivation)
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Single lead product in clinical development
- Limited financial resources
- High regulatory and clinical trial risk
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Funding constraints
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- RDHL
Competitive Landscape
Aprea Therapeutics faces intense competition from established pharmaceutical companies and other biotechnology firms developing cancer therapies. Its competitive advantage lies in targeting the p53 pathway, but clinical success is crucial.
Growth Trajectory and Initiatives
Historical Growth: Aprea Therapeutics has not demonstrated historical growth in terms of revenue, given its pre-commercial status.
Future Projections: Future growth depends on the successful development and commercialization of Eprenetapopt and other pipeline candidates. Analyst estimates vary widely and are highly speculative.
Recent Initiatives: Focus on advancing Eprenetapopt through clinical trials and exploring potential strategic partnerships.
Summary
Aprea Therapeutics is a clinical-stage company with a novel approach to cancer therapy by reactivating mutant p53. Its success hinges on favorable clinical trial outcomes for Eprenetapopt. The company has significant clinical and financial risks typical of its stage. Strategic partnerships and further funding will be crucial for long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated. Financial data may be outdated. Please consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aprea Therapeutics Inc
Exchange NASDAQ | Headquaters Doylestown, PA, United States | ||
IPO Launch date 2019-10-03 | Co-Founder, CEO, President & Director Dr. Oren Gilad Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://aprea.com |
Full time employees 8 | Website https://aprea.com | ||
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.